ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ALKS Stock Price » ALKS Stock News

Alkermes Share News

 Alkermes (mm) Stock Price
ALKS Stock Price
 Alkermes (mm) Stock Chart
ALKS Stock Chart
 Alkermes (mm) Stock News
ALKS Stock News
 Alkermes (mm) Company Information
ALKS Company Information
 Alkermes (mm) Stock Trades
ALKS Stock Trades

Alkermes, Elan Drug Technologies To Merge In $960 Million Transaction

DOW JONES NEWSWIRES Biotechnology company Alkermes Inc (ALKS) Monday said it will merge with Elan Drug Technologies (EDT), a unit of Elan Corp. (ELN), in a cash and stock transaction valued at $960 million. Alkermes and Elan Drug Technologies will be combined under a new holding company incorporated in Ireland, to be called Alkermes Plc, Alkermes and Elan said in a joint statement. As part of the transaction, which has been approved by the boards of Alkermes and Elan, Elan will receive $500 million in cash and a 25% equity stake in Alkermes Plc. The merger is expected to be immediately accretive to cash earnings and the combined company is expected to have revenue in excess of $450 million annually. "The merger will be financially transformative and create a profitable, global biopharmaceutical company with a diversified CNS (central nervous system) product portfolio and a strong foundation for growth," Alkermes Chief Executive Richard Pops said in the statement. Pops will become the chairman and chief executive of the new entity. In the merger transaction, existing shareholders of Alkermes will receive one ordinary share of Alkermes Plc in exchange for each share of Alkermes they own at the time of the merger. Alkermes Plc shares will be registered in the U.S. and are expected to trade on the NASDAQ . Alkermes has obtained a commitment from Morgan Stanley & Co. and HSBC to provide up to $450 million of term loans to finance the transaction, which is expected to close during the third quarter of 2011, subject to shareholder and regulatory approvals.

Stock News for Alkermes (ALKS)
DateTimeHeadline
11/15/201309:01:37HBK Investments LP 3Q 13F: Largest Eliminations
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Eliminations -2-
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Sales
11/15/201309:01:27HBK Investments LP 3Q 13F: Largest Purchases
11/15/201308:22:25Janus Capital Management 3Q 13F: Largest Purchases -2-
11/15/201308:22:24Janus Capital Management 3Q 13F: Largest Purchases
11/15/201308:22:24Janus Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:22:23Janus Capital Management 3Q 13F: Holdings As Of Sep 30
10/10/201309:29:34U.S. Hot Stocks Futures: Hot Stocks to Watch
05/31/201209:19:14US HOT STOCK FUTURES: HOT STOCKS TO WATCH
01/30/201217:42:15US Stocks Edge Lower As Europe's Debt Flashpoints Weigh
01/30/201208:02:33US Stock Futures Lower On Renewed Worries Over Greece
01/27/201216:12:26FDA Approves Amylin's Bydureon Diabetes Drug After Delays
07/28/201109:30:07Amylin, Eli Lilly And Alkermes Submit Reply To FDA On Bydureon
07/27/201105:30:27CORRECT: Elan Confirms Outlook As Quarterly Net Loss Narrows
07/18/201115:19:27Alkermes Sees Sales Growth After Merger With Elan Drug Tech
07/12/201110:09:05Elan To Close Pennsylvania Site Ahead Of Unit Sale To Alkermes
06/24/201119:46:35Amylin, MannKind Shares Rise On Diabetes Data Releases
06/21/201107:02:05Lilly, Amylin, Alkermes Diabetes Drug Gets EU Approval
05/09/201104:46:15Elan Sells EDT Unit To Alkermes To Generate Cash, Cut Debt

Alkermes and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad